Literature DB >> 25299467

The current place and indications of 131I-metaiodobenzylguanidine therapy in the era of peptide receptor radionuclide therapy: determinants to consider for evolving the best practice and envisioning a personalized approach.

Sandip Basu1, Amit Abhyankar, Prafful Jatale.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25299467     DOI： 10.1097/MNM.0000000000000209

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN： 0143-3636            Impact factor:   1.690


× No keyword cloud information.
  3 in total

Review 1.  Treatment for Malignant Pheochromocytomas and Paragangliomas: 5 Years of Progress.

Authors:  Paola Jimenez; Claudio Tatsui; Aaron Jessop; Sonali Thosani; Camilo Jimenez
Journal:  Curr Oncol Rep       Date:  2017-10-28       Impact factor: 5.075

Review 2.  Metastatic Phaeochromocytoma: Spinning Towards More Promising Treatment Options.

Authors:  Svenja Nölting; Ashley Grossman; Karel Pacak
Journal:  Exp Clin Endocrinol Diabetes       Date:  2018-09-20       Impact factor: 2.949

3.  Comparative evaluation of iodine-131 metaiodobenzylguanidine and 18-fluorodeoxyglucose positron emission tomography in assessing neural crest tumors: Will they play a complementary role?

Authors:  Soumyakanti Kundu; Purushottam Kand; Sandip Basu
Journal:  South Asian J Cancer       Date:  2017 Jan-Mar
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.